Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Tyler Research Institute LLC

Neither a doctor nor a teaching hospital

Research payments

$13,193,252

1,564 payments

Through program year 2025, Tyler Research Institute LLC is reported as receiving $13,193,252 in research payments, across 1,564 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,580,249 334
2024 Research $2,019,768 249
2023 Research $1,868,863 144
2022 Research $2,205,304 265
2021 Research $1,542,310 241
2020 Research $1,662,589 210
2019 Research $1,314,168 121

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $7,698,923 685 payments
  2. Janssen Research & Development, LLC $1,816,028 198 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $765,543 127 payments
  4. Eli Lilly and Company $719,031 22 payments
  5. Genentech, Inc. $679,022 177 payments
  6. F. Hoffmann-La Roche AG $498,338 37 payments
  7. Arena Pharmaceuticals, Inc. $342,090 99 payments
  8. Roche Products Limited $311,882 63 payments
  9. Pfizer Inc. $280,691 142 payments
  10. Sanofi US Services Inc. $61,420 10 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis $1,128,670 113 payments
  2. A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohns Disease $733,824 22 payments
  3. A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) $685,177 64 payments
  4. Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) $589,827 22 payments
  5. M14-433 $484,861 22 payments
  6. M14-675 $457,725 16 payments
  7. A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects $362,585 50 payments
  8. A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 $310,562 21 payments
  9. M14-430 $305,902 21 payments
  10. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease $294,748 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record